Johnson & Johnson vs Novavax Inc
JNJ vs NVAX — side-by-side comparison from reported financials. JNJ leads 5, NVAX leads 4 of 9 comparable metrics.
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
Novavax Inc
NVAX · Healthcare
$12.73+15.62%Strong
| Metric | JNJ | NVAX |
|---|---|---|
| Price | $261.79 | $12.73 |
| Market cap | $631B | $2.10B |
| Revenue (TTM) | $97.9B | $414M |
| Revenue growth | +5.6% | -17.2% |
| Net margin | 21.5% | -59.9% |
| Free cash flow | $22.2B | -$42.8M |
| Net cash (debt) | ($27.8B) | — |
| 1-year price return | +37.0% | +48.2% |
| P/E | 29.9 | 4.8 |
| P/E vs own history (cheap-side %) | 16% | 29% |
| Dividend yield | 2.00% | — |
| Return on equity | 26% | 283% |
| Altman Z-score | — | -5.14 |
| CV checks passed | 10 of 11 | 4 of 11 |
| Employees | 140,800 | 749 |
Full résumé-style profiles: JNJ CV · NVAX CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.